Restenosis after successful ostial stent implantation: The role of statins compared with conventional treatment

Journal of Interventional Cardiology

Volumn 17, Issue 5, 2004, Pages 301-306

  Horlitz, Marc ^a   Amin, Fouad R ^b   Boerrigter, Guido ^a   Sigwart, Ulrich ^b   Clague, Jonathan R ^b  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUINDOSTATIN; MEVINOLIN; NITRATE; PRAVASTATIN; SIMVASTATIN; STATINE; TICLOPIDINE; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTENOSIS; RETROSPECTIVE STUDY; UNITED KINGDOM;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STENTS; TREATMENT OUTCOME;

EID: 7444245646     PISSN: 08964327     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2004.00326.x     Document Type: Article

References (24)

1. Ryan TJ, Faxon DP, Gunnar RM. Guidelines for percutaneous transluminal coronary angioplasty: A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Cardiovascular Diseases, Vol. XXXIX, No. 2 (September/October), Philadelphia, PA, Saunders, 1996: pp. 83-110, Angioplasty). J Am Coll Cardiol 1998;12:529-545.
2. Douglas JS, Gruentzig AR, King SB. Percutaneous transluminal coronary angioplasty in patients with prior coronary bypass surgery. J Am Coll Cardiol 1983;2:745-754.
3. Weintraub WS, Boccuzzi SJ, Klein JL, et al., and the Lovastatin Restenosis Trial Study Group. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 1994;331:1331-1337.
4. O'Keefe JH, Stone GW, McCallister BD, et al. Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1996;77:649-652.
5. Bertrand ME, McFadden EP, Fruchart JC, et al., for the PREDICT Trial Investigators. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. J Am Coll Cardiol 1997;30:863-869.
6. Onaka H, Hirota Y, Kita Y. The effect of pravastatin on prevention of restenosis after successful percutaneous coronary angioplasty. Jpn Circ J 1994;58:100-106.
7. Serruys PW, Foley DP, Jackson G, et al., on behalf of the FLARE study group. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after coronary balloon angioplasty. Final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 1999;20:58-69.
8. Walter DH, Schächinger V, Elsner Met, et al. Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol 2000;85:962-968.
9. Zampieri P, Colombo A, Almagor Y, et al. Results of coronary stenting of ostial lesions. Am J Cardiol 1994;73:901-903.
10. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Study (4S). Lancet 1994;344:1383-1389.
11. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995;345:1274-1275.
12. Sacks FM, Pfeffer MA, Moye LA, et al., for the Cholesterol and recurrent Events Trial Investigators. N Engl J Med 1996;335:1001-1009.
13. Gellmann J, Ezekowitz MD, Sarembock IJ, et al. Effect of lovastatin on intimal hyperplasia after balloon angioplasty: A study in an atherosclerotic hypercholesterolemic rabbit. J Am Coll Cardiol 1991;17:251-259.
14. Eckardt H, Voelker W, Bruenning T, et al. Lovastatin reduces myointimal proliferation after vascular injury (abstract). Eur Heart J 1991;12:(Suppl.):9.
15. Kereiakes DJ. Percutaneous transcatheter therapy of aortoostial stenoses. Cathet Cardiovasc Diagn 1996;38:292-300.
16. Katoh O, Reifert N. New double wire technique to stent ostial lesions. Cathet Cardiovasc Diagn 1997;40:400-402.
17. Margolis JR, Gallarello F. Treatment of ostial lesions. J Interv Cardiol 1998;11:549-556.
18. Sigwart U. Ten years of stenting: What next? J Interv Cardiol 1997;10:195-205.
19. Tan KH, Sulke N, Taub N, et al. Percutaneous transluminal coronary angioplasty of aorta ostial, non-ostial, and branch ostial stenoses: Acute and long-term outcome. Eur Heart J 1995;16:631-639.
20. Horlitz M, Amin FR, Sigwart U, et al. Coronary stenting of aorto-ostial saphenous vein graft lesions. J Interv Cardiol 2000;13:303-308.
21. Hong MK, Haudenschild CC, Tjurmin A. Why do aorto-ostial lesions behave differently than non-ostial lesions? Histologic findings in directional atherectomy specimens of aorto-ostial vs. non-ostial lesions. J Am Coll Cardiol 1995:138A.
22. Rocha-Singh K, Morris N, Wong C, et al. Coronary stenting for treatment of ostial stenoses of native coronary arteries or aortocoronary saphenous vein grafts. Am J Cardiol 1995;75:26-29.
23. Zampieri P, Colombo A, Almagor Y, et al. Results of coronary stenting of ostial lesions. Am J Cardiol 1994;73:901-903.
24. Bunch TJ, Muhlestein JB, Anderson JL, et al. Effects of statins on six-month survival and clinical restenosis frequency after coronary stent deployment. Am J Cardiol 2002;90:299-302.